Dexamethasone intravitreal implant for macular edema following retinal vein occlusion

Retinal vein occlusion is a major cause of vision loss worldwide, second only to diabetic retinopathy among retinal vascular disorders. A novel bioerodable corticosteroid implant composed of 0.7 mg dexamethasone designed for in-office injection has recently been approved for the treatment of macular edema resulting from retinal vein occlusion, a major mechanism for decreased vision in the condition. Following a single injection, subjects in the Phase III clinical trial achieved three lines of visual acuity improvement significantly faster than subjects who received sham injection. Following repeat injection 6 months later, subjects achieved similar gains with manageable levels of increased intraocular pressure and cataract development. The dexamethasone intravitreal implant is an important option in the management of macular edema following retinal vein occlusion.

[1]  F. Bandello,et al.  Macular hole after injection of dexamethasone intravitreal implant for macular oedema due to central retinal vein occlusion , 2013, Acta ophthalmologica.

[2]  R. Gallego-Pinazo,et al.  Anterior chamber migration of dexametasone intravitreal implant (Ozurdex®) , 2012, Graefe's Archive for Clinical and Experimental Ophthalmology.

[3]  S. Bakri,et al.  Evolution of vitreomacular traction following the use of the dexamethasone intravitreal implant (Ozurdex) in the treatment of macular edema secondary to central retinal vein occlusion. , 2012, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[4]  J. Crespí,et al.  Repositioning of dexamethasone intravitreal implant (Ozurdex®) migrated into the anterior chamber , 2012, International Ophthalmology.

[5]  Angela M. Herro,et al.  OPTICAL COHERENCE TOMOGRAPHY IN RETINITIS PIGMENTOSA: Reproducibility and Capacity to Detect Macular and Retinal Nerve Fiber Layer Thickness Alterations , 2012, Retina.

[6]  P. Mitchell,et al.  Effect of the duration of macular edema on clinical outcomes in retinal vein occlusion treated with dexamethasone intravitreal implant. , 2012, Ophthalmology.

[7]  J. Haller,et al.  Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study. , 2012, Ophthalmology.

[8]  P. Campochiaro,et al.  Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. , 2012, Ophthalmology.

[9]  S. Seregard,et al.  Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double-masked clinical study. , 2012, Ophthalmology.

[10]  M. Parodi,et al.  Rebound effect after intravitreal dexamethasone implant for the treatment of macular edema secondary to central retinal vein occlusion. , 2012, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[11]  M. Blumenkranz,et al.  Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. , 2011, Ophthalmology.

[12]  R. Bansal,et al.  Wandering Ozurdex® implant , 2011, Journal of Ophthalmic Inflammation and Infection.

[13]  N. Bressler,et al.  Does laser still have a role in the management of retinal vascular and neovascular diseases? , 2011, American journal of ophthalmology.

[14]  P. Campochiaro,et al.  Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. , 2011, Ophthalmology.

[15]  Justis P. Ehlers,et al.  Retinal vein occlusion: beyond the acute event. , 2011, Survey of ophthalmology.

[16]  P. Keane,et al.  Retinal vein occlusion and macular edema – critical evaluation of the clinical value of ranibizumab , 2011, Clinical ophthalmology.

[17]  H. Tabandeh,et al.  DEXAMETHASONE INTRAVITREAL IMPLANT FOR TREATMENT OF DIABETIC MACULAR EDEMA IN VITRECTOMIZED PATIENTS , 2011, Retina.

[18]  G. Shah,et al.  Efficacy of intravitreal bevacizumab after unresponsive treatment with intravitreal ranibizumab. , 2011, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie.

[19]  J. Haller,et al.  The dexamethasone drug delivery system: Indications and evidence , 2011, Advances in therapy.

[20]  N. Bressler,et al.  Management of macular edema from retinal vein occlusions: you can never have too many choices. , 2010, Ophthalmology.

[21]  P. Campochiaro,et al.  Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. , 2010, Ophthalmology.

[22]  P. Mitchell,et al.  Natural history of branch retinal vein occlusion: an evidence-based systematic review. , 2010, Ophthalmology.

[23]  M. Blumenkranz,et al.  Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. , 2010, Ophthalmology.

[24]  Sarah Gray,et al.  Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. , 2010, Ophthalmology.

[25]  S. Whitcup,et al.  Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. , 2010, Investigative ophthalmology & visual science.

[26]  Jean-Pierre Hubschman,et al.  Ultra wide-field angiographic characteristics of branch retinal and hemicentral retinal vein occlusion. , 2010, Ophthalmology.

[27]  N. Kuno,et al.  Biodegradable Intraocular Therapies for Retinal Disorders , 2010, Drugs & aging.

[28]  Tien Yin Wong,et al.  The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. , 2010, Ophthalmology.

[29]  Ingrid U Scott,et al.  A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. , 2009, Archives of ophthalmology.

[30]  George A. Williams,et al.  Dexamethasone posterior-segment drug delivery system in the treatment of macular edema resulting from uveitis or Irvine-Gass syndrome. , 2009, American journal of ophthalmology.

[31]  J. Haller,et al.  EVALUATION OF THE SAFETY AND PERFORMANCE OF AN APPLICATOR FOR A NOVEL INTRAVITREAL DEXAMETHASONE DRUG DELIVERY SYSTEM FOR THE TREATMENT OF MACULAR EDEMA , 2009, Retina.

[32]  J. Jonas,et al.  Intraocular concentration of triamcinolone acetonide after intravitreal injection in the rabbit eye. , 2008, Ophthalmology.

[33]  Ming-ming Li,et al.  Dexamethasone inhibits leukocyte accumulation and vascular permeability in retina of streptozotocin-induced diabetic rats via reducing vascular endothelial growth factor and intercellular adhesion molecule-1 expression. , 2008, Biological & pharmaceutical bulletin.

[34]  S. Fekrat,et al.  Fluocinolone acetonide sustained drug delivery device for chronic central retinal vein occlusion: 12-month results. , 2008, American journal of ophthalmology.

[35]  Ronald Klein,et al.  The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study. , 2008, Archives of ophthalmology.

[36]  M. Garabedian,et al.  Activation of Trk neurotrophin receptors by glucocorticoids provides a neuroprotective effect , 2008, Proceedings of the National Academy of Sciences.

[37]  M. Gillies,et al.  Intravitreal Triamcinolone Acetonide Inhibits Breakdown of the Blood-Retinal Barrier Through Differential Regulation of VEGF-A and Its Receptors in Early Diabetic Rat Retinas , 2008, Diabetes.

[38]  J. Pulido,et al.  Pharmacokinetics of intravitreal ranibizumab (Lucentis). , 2007, Ophthalmology.

[39]  Sharon D. Solomon,et al.  Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[40]  George A. Williams,et al.  Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. , 2007, Archives of ophthalmology.

[41]  J. Pulido,et al.  Role of inflammation in retinal vein occlusion. , 2007, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie.

[42]  P. Mulder,et al.  Intravitreal dexamethasone as adjuvant in the treatment of postoperative endophthalmitis: a prospective randomized trial , 2005, Graefe's Archive for Clinical and Experimental Ophthalmology.

[43]  G. Hutchins,et al.  CENTRAL RETINAL VEIN OCCLUSION: A Prospective Histopathologic Study of 29 Eyes in 28 Cases , 2005, Retina.

[44]  U. Kompella,et al.  Budesonide reduces vascular endothelial growth factor secretion and expression in airway (Calu-1) and alveolar (A549) epithelial cells. , 2001, European journal of pharmacology.

[45]  Y. Yun,et al.  Inhibitory effects of anti-inflammatory drugs on interleukin-6 bioactivity. , 2001, Biological & pharmaceutical bulletin.

[46]  R. Folberg,et al.  Vascular endothelial growth factor upregulation in human central retinal vein occlusion. , 1998, Ophthalmology.

[47]  G. Karakiulakis,et al.  Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. , 1998, European journal of pharmacology.

[48]  M. Billah,et al.  The inhibitory effects of topically active glucocorticoids on IL-4, IL-5, and interferon-gamma production by cultured primary CD4+ T cells. , 1997, The Journal of allergy and clinical immunology.

[49]  Hidehiro Ishii,et al.  Vascular Endothelial Growth Factor–Induced Retinal Permeability Is Mediated by Protein Kinase C In Vivo and Suppressed by an Orally Effective β-Isoform–Selective Inhibitor , 1997, Diabetes.

[50]  David J. Wilson,et al.  Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M report. , 1995, Ophthalmology.

[51]  K. Eakins,et al.  A comparison of the ocular anti-inflammatory activity of steroidal and nonsteroidal compounds in the rat. , 1983, Investigative ophthalmology & visual science.

[52]  R. E. Kalina,et al.  Dexamethasone inhibition of experimental endothelial cell proliferation in retinal venules. , 1978, Investigative ophthalmology & visual science.

[53]  G. Jaffe,et al.  Prospective study of a fluocinolone acetonide implant for chronic macular edema from central retinal vein occlusion: thirty-six-month results. , 2012, Ophthalmology.

[54]  Allen C Ho,et al.  Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. , 2011, Ophthalmology.

[55]  M. Nakayama,et al.  Comparison of inducibility of CYP1A and CYP3A mRNAs by prototypical inducers in primary cultures of human, cynomolgus monkey, and rat hepatocytes. , 2007, Drug metabolism and pharmacokinetics.

[56]  I. MacDonald,et al.  In Memoriam: Dr. Lois Lloyd and Dr. Ronald Casey , 2007 .